{"name":"Vaxxinity, Inc.","slug":"vaxxinity-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BNT162b2 vaccine","genericName":"BNT162b2 vaccine","slug":"bnt162b2-vaccine","indication":"Prevention of COVID-19 in individuals 12 years of age and older","status":"marketed"},{"name":"ChAdOx1-S vaccine","genericName":"ChAdOx1-S vaccine","slug":"chadox1-s-vaccine","indication":"COVID-19 prevention (Phase 3 development)","status":"phase_3"},{"name":"Sinopharm BIBP","genericName":"Sinopharm BIBP","slug":"sinopharm-bibp","indication":"COVID-19 prevention in adults and pediatric populations","status":"phase_3"}]}],"pipeline":[{"name":"BNT162b2 vaccine","genericName":"BNT162b2 vaccine","slug":"bnt162b2-vaccine","phase":"marketed","mechanism":"Not specified","indications":["Prevention of COVID-19 in individuals 12 years of age and older","Prevention of COVID-19 in individuals 5 years of age and older","Prevention of COVID-19 in individuals 6 months through 4 years of age"],"catalyst":""},{"name":"ChAdOx1-S vaccine","genericName":"ChAdOx1-S vaccine","slug":"chadox1-s-vaccine","phase":"phase_3","mechanism":"ChAdOx1-S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate adaptive immune responses against COVID-19.","indications":["COVID-19 prevention (Phase 3 development)"],"catalyst":""},{"name":"Sinopharm BIBP","genericName":"Sinopharm BIBP","slug":"sinopharm-bibp","phase":"phase_3","mechanism":"Sinopharm BIBP is a COVID-19 inactivated vaccine that stimulates immune responses against SARS-CoV-2 by presenting inactivated viral particles to the immune system.","indications":["COVID-19 prevention in adults and pediatric populations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOWm04emFZVFdWTUZEMEVaYmlpRFo5N24yc0dKeURtOEwxYlpNZmV0OEEwYmtjamJYTzd3WlFpR2RMTHpTUUx0U1Q0VFhJZGw0RkZoaDlFNGxoTXFEZFZMcHpjQXJvUWJ1NmUzLWFBT2VhbWRmMWxqRy1NcW9pY2h1LVhGblB1MHg2RjJ4R1JTWEFleUk0NGdpUC1hSmk?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Hypercholesterolemia Clinical Trial Pipeline Shows Potential - openPR.com","headline":"Hypercholesterolemia Clinical Trial Pipeline Shows Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1LQVoyb2JPeGZ0Wm4xSFdieldXRnpkbFRtdmZxaTJtb05MNEZhY29VQUs1QS0tYzJfakJfLWF6a1BSdDNJLXk4bjZXNTNjdlZKQUVPT3FCWE43eUdNMVFEZW5aZEVLZw?oc=5","date":"2025-07-18","type":"pipeline","source":"timothysykes.com","summary":"Top 6 Healthcare Stock Picks in 2025 - timothysykes.com","headline":"Top 6 Healthcare Stock Picks in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNUk0yZ0NoT2RGSnQ4ZUVEVWtNbUJhekFjRzJUSVJvb3FpXzkxZTFHN1FoWmZZd3VzWld2YTJVZzBOSk00OFRJZ0habXlxQ3FxNEdQM1ZsSS1KMWZEUUNhZmNfLW42OTdKdzdhWjVaamJ0cXpfUzdTMU5rRFJTSWpnNUJzbnIyMFpZM1pjM0Qtc19JMkdlTmZHQVFhZkNKbm1UUjhyTzB6aHNKemJnaXp4Y2p5aU5EZkktN0d3b0k2VGx6QlVqZ1NTMm93WkF0b1JaMWZySUVKTWZvSkZGZXotTUlNbHhHU0VhWjVFT0RoRHBFdl9faExHWEpHbmdmVHRfWVAzV19HMA?oc=5","date":"2024-09-26","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Mixed fortunes for the neurodegeneration therapy pipeline in 2024 - drugdiscoverytrends.com","headline":"Mixed fortunes for the neurodegeneration therapy pipeline in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE96QzctMVVrVkdSdlNNanFSN1pxOE5HMG1tbVl1b2VzVGhFd1ExUV93enRucVNGalZvQlNJTW9ZMF80NmRSTlo3OWpIQTdUb0NlSkVvWWxkRGR1RHBCQnRJRnR1am13QQ?oc=5","date":"2024-07-01","type":"pipeline","source":"The Pharma Letter","summary":"Vaxxinity - The Pharma Letter","headline":"Vaxxinity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOQzJVZWVYNTVqN0RqV0UwREdhYm5kRkVNU2pYU2pCbU5wck1rU0czZjVCYmMwNjJ6NVVScVFPeENwMkpUeHlDaUQ5Zm12NHdTN3BsTnRGeGVzMVA4dmxCbVJrUmVHeUNrZTBKSXY3ajUzME9feVJsM0lVS2RNOVNmSS1JYW9LdmNZc2E1ZlFHVXA3aEMzdTl2dWJIZml0Ql9ZSUJaWHRnam5xZw?oc=5","date":"2024-05-15","type":"pipeline","source":"Fierce Biotech","summary":"Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech","headline":"Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFBKZlZmZ1hoYi02VzRYcC1fQzJqdTRXMTVEMkxJOUM2c0tqbnhkYWVwdnhYZTByRnFJMG00dnhsbHV2UEh1TWl1bTBhaTJJWk9wanowTnkwU2Y?oc=5","date":"2024-05-12","type":"pipeline","source":"TradingView","summary":"VAXX Stock Price and Chart — OTC:VAXX - TradingView","headline":"VAXX Stock Price and Chart — OTC:VAXX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaXhrR09wWGM3eUE4RUMzN0RwUEF4allJR2JsR21TbGwwYmVJVV9YUC0zek9mcTA2TTZkOW9iUUN5WjJKVDhrYXVBbTJaQThnR3JWSVhSamJVUExXOGlCdkdRQUNrTVp4MFBEMjhNTEt0aE8za21wckhCZW1SMzdtVU9nVHF4TmttODhfRi00ZS1pLU5mT1RPb3FZSHVHUUhtVnJZZTRleVd6UEE?oc=5","date":"2024-04-19","type":"pipeline","source":"globenewswire.com","summary":"Vaxxinity Issues Shareholder Letter - globenewswire.com","headline":"Vaxxinity Issues Shareholder Letter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNdlE3TVBISndnMlFMaW12LXpUTkJYd092Zmg4aE1EXzFURk1vekQ5WktkZUJQUzk3Wm5xUXJCNU9XZXU5UTFoOUtpOS0xOENzVlJCWlpFYjIyTThKMnZ3dHlCZzRKYmJPaFdwT0g1Z3gyb2xDVy0xWTYwdkRQemtoU0lGcExfTWxsaFByLWw3V2dhR2FiM19kbks1ZmNxQXFZbFFSd3dkbk81TW9QZ1ZHZUI0SnpQT1U?oc=5","date":"2024-03-08","type":"trial","source":"Pharmaceutical Technology","summary":"AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology","headline":"AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRC1EN0ljYk1MZHRtM1JoanlRMlFGQVNWSlRSTXBtX1lJdlV5Ykc1cm5MeVZzTTlUYVVqTThKOXB6dE1PdzhRTlZLVmtFVTlqMlJXYTNkdjJlMkxBTXF6NXF3cGNvQ2lqT25kNF9lZENIaGdiSnFTT2k2dUxzOWRTR2pGc05LcndG?oc=5","date":"2022-01-14","type":"pipeline","source":"Pharma Voice","summary":"Vaxxinity looks to pioneer the next revolution in pharma - Pharma Voice","headline":"Vaxxinity looks to pioneer the next revolution in pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOZTBrdEltOWt1VUo5T2ZReV9Fd0pnRkdjX3BrZXFpVVZtZmJWQ2Z0cFlwQTJDSTJKUHNSbEwyN1R6VU5DQXNhdUIzV3hrbjctNEVUbkU1Z29Yd2MySmJwQkItVnF1ZTg4WldtdF8zdGhvbjlGZzNKZ1hfamp6SnlITHJPaEFTRnVJS1hRdHhvUUc1NXRHdkg3YWFNLUN4WFB3dDZ6Qkln?oc=5","date":"2021-11-11","type":"pipeline","source":"MedCity News","summary":"With claims of potential Alzheimer’s edge, Vaxxinity squeaks out $78M IPO - MedCity News","headline":"With claims of potential Alzheimer’s edge, Vaxxinity squeaks out $78M IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQSDVUZS05UUV5LWNIV0V6T1FUZ0hoSWpvRUtTVXNJWFZBWlQ3T0t1aklvUVRnbXVvTERNNFhZeVRhTjVGWWQxdkxrWE91UHlOek9YMV9ydnY0dS1QRlJxWkNvZ19ZR2QzVjFrQ3pVMnlqTWdKTVkxOVJDbVVFNndqRU11d3dSazZWWnBWTlFjTlVWSnhrcEdvWFBMUWEzTnhteGd0Z2lWZ2JOazA1TFYtZ0JrdHJZUmlTbmhCZVFMWi1LaWc2NXFLWVJkS3lMalVGaS0zZk5LcFFrT0dvQzZSc1AxXzNMbGhmTUJDYXhfQmZzVkpFSDdXTzV4bzNrV05leHlTXzFDVkU?oc=5","date":"2021-06-21","type":"pipeline","source":"Business Wire","summary":"Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccine - Business Wire","headline":"Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNX3RyOFJqRDAxNkRXNzFUZmpJZnJPaExkV3FEYWJtUzZSRTZhSFFBZC10V1lZNno4X0ZGX2lRcUplVUxoMGhXQll3R1NyMUdJV3FuM1hXdmhXZUEtZDdiUE4tTzBkWHFjb1IySlJrbl94MzB0ZEJMcEJiUWl1Q19nenR6bm9yelBNenFvRmJEWHRKdTk3N3V3dkdRNlQ4aXBDTWhDRVAyTDBST1F2NGhTdEptaGttZw?oc=5","date":"2021-05-19","type":"trial","source":"Clinical Trials Arena","summary":"Vaxxinity CEO Mei Mei Hu on vaccine research and democratising health - Clinical Trials Arena","headline":"Vaxxinity CEO Mei Mei Hu on vaccine research and democratising health","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}